Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence.

Omaer, Abubker; Albilali, Abdulrazaq; Bamogaddam, Reem; Almutairi, Fares; Alsaif, Raghad; Almohammadi, Osama; Alhifany, Abdullah A

Omaer, Abubker; Albilali, Abdulrazaq; Bamogaddam, Reem; Almutairi, Fares; Alsaif, Raghad; Almohammadi, Osama; Alhifany, Abdullah A.

Afiliação

Omaer A; Clinical Pharmacy Department, King Saud Medical City, Riyadh, Saudi Arabia.
Albilali A; Neurology Unit, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Bamogaddam R; Clinical Pharmacy Department, King Saud Medical City, Riyadh, Saudi Arabia.
Almutairi F; Clinical Pharmacy Department, King Saud Medical City, Riyadh, Saudi Arabia.
Alsaif R; Clinical Pharmacy Department, King Saud Medical City, Riyadh, Saudi Arabia.
Almohammadi O; Pharmacy Department, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.
Alhifany AA; Pharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.

Saudi Pharm J ; 32(4): 101989, 2024 Apr.

Article em En | MEDLINE | ID: mdl-38405041

Palavras-chave

Anxiety; Depression; Eptinezumab; Erenumab; Fremanezumab; Galcanezumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Saudi Pharm J Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Arábia Saudita

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google